NCT05132127View on ClinicalTrials.gov

Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

November 15, 2022

Study Completion Date

November 15, 2022

Conditions
Cold Agglutinin Disease
Interventions
DRUG

sutimlimab

Pharmaceutical form: solution for injection Route of administration: intravenous (IV)

Trial Locations (5)

920-8530

Investigational Site Number 3920005, Ishikawa

259-1193

Investigational Site Number 3920004, Kanagawa

565-0871

Investigational Site Number 3920003, Osaka

350-0495

Investigational Site Number 3920002, Saitama

113-8431

Investigational Site Number 3920001, Tokyo

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY